Skip to main content
VivoSim Labs, INC. logo

VivoSim Labs, INC. — Investor Relations & Filings

Ticker · VIVS ISIN · US68620A2033 US Professional, scientific and technical activities
Open in API
Filings indexed 790 across all filing types
Latest filing 2017-04-24 Director's Dealing
Country US United States of America
Listing US VIVS

About VivoSim Labs, INC.

https://organovo.com/

VivoSim Labs, Inc. is a biotechnology services company that develops and utilizes bioprinted, three-dimensional (3D) human tissues designed to emulate human biology and disease. The company provides testing services for drugs and drug candidates, primarily for the pharmaceutical and biotechnology sectors. VivoSim Labs specializes in offering liver and intestinal toxicology insights through its proprietary New Approach Methodologies (NAMs), including its NAMkind™ 3D models. These non-animal testing platforms are used to generate human-relevant safety and toxicology data early in the drug discovery and development process, aiming to provide insights before animal studies or clinical trials.

Recent filings

Filing Released Lang Actions
FORM 3 SUBMISSION
Director's Dealing
2017-04-24 English
FORM S-8
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans or inducement awards. It includes detailed information about stock option agreements and restricted stock unit awards granted to a new CEO as inducements for employment. The document references the Securities Act of 1933 and Nasdaq Listing Rule 5635(c)(4). It is not an annual report, earnings release, or any other financial report but a registration statement related to capital raising through stock awards. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed registration information, not just an announcement or certification, so it is not RPA or RNS.
2017-04-24 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 7, 2017, for Organovo Holdings, Inc. The content focuses on the departure of the current CEO and president, Keith Murphy, and the appointment of a new CEO and president, Taylor J. Crouch. It details the terms of the separation agreement, consulting agreement, offer letter for the new CEO, and related compensation and severance plans. The document also includes information about the board membership changes and related agreements. There are no financial statements or financial performance data presented; rather, the document is primarily an announcement of changes in senior management and board composition. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). Therefore, the appropriate classification is MANG with high confidence.
2017-04-11 English
FORM 4 SUBMISSION
Director's Dealing
2017-02-22 English
FORM 4 SUBMISSION
Director's Dealing
2017-02-22 English
FORM 4 SUBMISSION
Director's Dealing
2017-02-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.